ADVAIR DISKUS ADVAIR - GlaxoSmithKline
ADVAIR DISKUS ADVAIR - GlaxoSmithKline
ADVAIR DISKUS ADVAIR - GlaxoSmithKline
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Drug-Drug Interactions<br />
Table 5<br />
Established or Potential Drug-Drug Interactions<br />
Drug Type Ref Effect Clinical comment<br />
Sympathomimetic<br />
agents<br />
Mono amine<br />
Oxidase Inhibitors<br />
or Tricyclic<br />
Antidepressants<br />
CT<br />
CS<br />
May lead to<br />
deleterious<br />
cardiovascular<br />
effects.<br />
Action of<br />
salmeterol on<br />
vascular system<br />
may be<br />
potentiated.<br />
Aerosol bronchodilators of the rapid onset, short<br />
duration adrenergic stimulant type may be used<br />
for relief of breakthrough symptoms while using<br />
salmeterol for asthma. Increasing use of such<br />
preparations to control symptoms indicates<br />
deterioration of disease control and the patient’s<br />
therapy plan should be reassessed. The regular,<br />
concomitant use of salmeterol and other<br />
sympathomimetic agents is not recommended.<br />
Salmeterol should be administered with extreme<br />
caution to patients being treated with<br />
monoamine oxidase inhibitors or tricyclic<br />
antidepressants, or within 2 weeks of<br />
discontinuation of such agents.<br />
Methylxanthines CT Unknown The concurrent use of intravenously or orally<br />
administered methylxanthines (e.g.,<br />
aminophylline, theophylline) by patients<br />
receiving salmeterol has not been completely<br />
evaluated.<br />
Beta-Blockers CS May antagonise<br />
the<br />
bronchodilating<br />
action of<br />
salmeterol.<br />
Acetylsalicylic<br />
acid<br />
T<br />
Non-selective beta-blocking drugs, should never<br />
be prescribed in asthma or COPD.<br />
Cardioselective beta-blocking drugs should be<br />
used with caution in patients with asthma or<br />
COPD.<br />
Use with caution in conjunction with<br />
corticosteroids in hypoprothrombinemia.<br />
Ritonavir<br />
CT &<br />
postmarketing<br />
Systemic effects<br />
including<br />
Cushings<br />
syndrome and<br />
adrenal<br />
suppression.<br />
Concomitant use of fluticasone propionate and<br />
ritonavir should be avoided. (See DRUG<br />
INTERACTIONS, Overview)<br />
Other inhibitors of<br />
cytochrome P450<br />
3A4<br />
CT<br />
Increased systemic<br />
exposure to<br />
salmeterol<br />
xinafoate and<br />
fluticasone<br />
propionate.<br />
Caution is advised when co-administering<br />
potent cytochrome P450 3A4 inhibitors (e.g.<br />
ketoconazole). (See DRUG INTERACTIONS,<br />
Overview, WARNINGS AND PRECAUTIONS<br />
and ACTION AND CLINIAL<br />
PHARMACOLOGY, Pharmacokinetics)<br />
Legend: C = Case Study; CT = Clinical Trial; T = Theoretical; CS = Class Statements<br />
July 29, 2014<br />
Page 25 of 67